| The continuing epidemic threat of novel coronaviruses to global health-the latest novel coronavirus outbreak in Wuhang, China DS Hui, E Ei Azhar, TA Madani, F Ntoumi, RA Kock, O Dar, G Ippolito, ... International Journal of Infectious Diseases 91, 1920 | 4297* | 1920 |
| The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China DS Hui, EI Azhar, TA Madani, F Ntoumi, R Kock, O Dar, G Ippolito, ... International journal of infectious diseases 91, 264-266, 2020 | 4295 | 2020 |
| Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts J Chakaya, M Khan, F Ntoumi, E Aklillu, R Fatima, P Mwaba, N Kapata, ... International Journal of Infectious Diseases, 2021 | 1110 | 2021 |
| Treatment of highly drug-resistant pulmonary tuberculosis F Conradie, AH Diacon, N Ngubane, P Howell, D Everitt, AM Crook, ... New England Journal of Medicine 382 (10), 893-902, 2020 | 886 | 2020 |
| Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis SH Gillespie, AM Crook, TD McHugh, CM Mendel, SK Meredith, ... New England Journal of Medicine 371 (17), 1577-1587, 2014 | 743 | 2014 |
| Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test SD Lawn, P Mwaba, M Bates, A Piatek, H Alexander, BJ Marais, ... The Lancet infectious diseases 13 (4), 349-361, 2013 | 636 | 2013 |
| High-dose rifapentine with moxifloxacin for pulmonary tuberculosis A Jindani, TS Harrison, AJ Nunn, PPJ Phillips, GJ Churchyard, ... N Engl J Med 371, 1599-1608, 2014 | 517 | 2014 |
| New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects AI Zumla, SH Gillespie, M Hoelscher, PPJ Philips, ST Cole, I Abubakar, ... The Lancet infectious diseases 14 (4), 327-340, 2014 | 434 | 2014 |
| Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies S Tiberi, N du Plessis, G Walzl, MJ Vjecha, M Rao, F Ntoumi, S Mfinanga, ... The Lancet Infectious Diseases 18 (7), e183-e198, 2018 | 406 | 2018 |
| A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis MJ Boeree, AH Diacon, R Dawson, K Narunsky, J Du Bois, A Venter, ... American journal of respiratory and critical care medicine 191 (9), 1058-1065, 2015 | 379 | 2015 |
| Drug-resistant tuberculosis: time for visionary political leadership I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ... The Lancet infectious diseases 13 (6), 529-539, 2013 | 378 | 2013 |
| Tuberculosis: advances and challenges in development of new diagnostics and biomarkers G Walzl, R McNerney, N du Plessis, M Bates, TD McHugh, NN Chegou, ... The Lancet Infectious Diseases 18 (7), e199-e210, 2018 | 364 | 2018 |
| Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis OJ Billington, TD McHugh, SH Gillespie Antimicrobial agents and chemotherapy 43 (8), 1866, 1999 | 340 | 1999 |
| Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples AC Brown, JM Bryant, K Einer-Jensen, J Holdstock, DT Houniet, ... Journal of clinical microbiology 53 (7), 2230, 2015 | 325 | 2015 |
| Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD DS Garcha, SJ Thurston, ARC Patel, AJ Mackay, JJP Goldring, ... Thorax 67 (12), 1075-1080, 2012 | 296 | 2012 |
| Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities R McNerney, M Maeurer, I Abubakar, B Marais, TD Mchugh, N Ford, ... Journal of Infectious Diseases 205 (suppl_2), S147-S158, 2012 | 283 | 2012 |
| Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future N Kapata, C Ihekweazu, F Ntoumi, T Raji, P Chanda-Kapata, P Mwaba, ... International Journal of Infectious Diseases 93, 233-236, 2020 | 267 | 2020 |
| Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial A Story, RW Aldridge, CM Smith, E Garber, J Hall, G Ferenando, L Possas, ... The Lancet 393 (10177), 1216-1224, 2019 | 255 | 2019 |
| The transmission of Mycobacterium tuberculosis in high burden settings TA Yates, PY Khan, GM Knight, JG Taylor, TD McHugh, M Lipman, ... The Lancet infectious diseases 16 (2), 227-238, 2016 | 245 | 2016 |
| Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study JM Bryant, SR Harris, J Parkhill, R Dawson, AH Diacon, P van Helden, ... The Lancet Respiratory Medicine 1 (10), 786-792, 2013 | 243 | 2013 |
Stephen H. GillespieUniversity of St AndrewsEmail verificata su st-andrews.ac.uk
